Alberta Regulator Dismisses Curaleaf Challenge to Aurora's ATM Program
ACB sits 53% above its 52-week low of $2.56 on light trading volume (0.2× avg).
Summary
Alberta's securities regulator dismissed Curaleaf's application against Aurora's ATM program. Aurora reaffirmed the ATM has not been used since August 18, 2026, and continues to urge shareholders to reject Curaleaf's revised US$5.00-per-share hostile bid.
Key Events · M&A and Partnerships · ACB
-
Regulator Dismisses Curaleaf ATM Challenge
The Alberta Securities Commission dismissed Curaleaf's application concerning Aurora's at-the-market program and ruled in favour of the Company, confirming the program is compliant with securities laws.
-
ATM Unused During Hostile Bid
Aurora reaffirmed that the last day it used the ATM was August 18, 2026, and that the program has not been used during the hostile bid process.
-
Board Rejects Revised US$5.00 Bid
The board unanimously recommends shareholders reject Curaleaf's revised hostile bid and take no action, and urges any who tendered to withdraw their shares.
-
Strategic Alternatives Continue
Aurora says all available strategic alternatives are still being considered, with details in the October 15, 2026 Notice of Change to the Directors' Circular.
Analysis · ACB · Life Sciences
A regulatory lever Curaleaf was using to pressure Aurora during its US$5.00-per-share hostile bid is now gone: the Alberta Securities Commission threw out Curaleaf's application to halt Aurora's at-the-market program. The ruling protects optionality rather than reflecting active dilution, since Aurora also confirmed the ATM has sat unused since August 18, 2026. Shareholders are still being urged by a unanimous board to reject the bid and take no action, and the strategic-alternatives process continues.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $258M. The 52-week trading range was $2.56 to $6.36. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.